Omeros has been granted a patent for a method to treat graft-versus-host disease and other conditions post hematopoietic stem cell transplant. The method involves administering a MASP-2 inhibitory agent to inhibit complement activation. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Omeros Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Omeros, Peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of February 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Treating diffuse alveolar hemorrhage with masp-2 inhibitory antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Omeros Corp

A recently granted patent (Publication Number: US11896621B2) discloses a method for treating diffuse alveolar hemorrhage associated with hematopoietic stem cell transplant in human subjects. The method involves administering a composition containing a MASP-2 inhibitory antibody or its antigen-binding fragment to inhibit MASP-2-dependent complement activation. The antibody can be a monoclonal antibody specifically binding to human MASP-2, with various forms such as recombinant, chimeric, humanized, or human antibodies being suitable for use.

Furthermore, the method includes identifying subjects at risk for diffuse alveolar hemorrhage before administering the MASP-2 inhibitory antibody systemically. The antibody used in the treatment does not substantially inhibit the classical pathway and effectively inhibits C3b deposition in human serum. The patent also covers cases where the subject has undergone or will undergo a hematopoietic stem cell transplant, emphasizing the importance of this method in managing complications associated with such procedures. The specific amino acid sequences of the antibody variable regions are also disclosed in the claims, providing detailed information on the composition used in the treatment process.

To know more about GlobalData’s detailed insights on Omeros, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies